Research shows PRMT1 drives thromboinflammation and drug resistance in platelets from diabetic and septic conditions, indicating potential therapeutic targets.
Key Points
The research aims to elucidate the role of PRMT1 in platelet hyperactivity and antiplatelet drug resistance in metabolic diseases.
Utilized megakaryocyte-specific PRMT1 overexpression and knockout mouse models.
Conducted aggregometer and bioflux assays to assess platelet aggregation.
Performed proteomic profiling of platelets to identify pathways related to inflammation and thromboxane production.
PRMT1 was found to enhance thrombin-mediated platelet aggregation and clot formation.
Knockout of Prmt1 resulted in prolonged bleeding times and reduced platelet aggregation.